DK1345609T3 - Tetrahydro-(benzo eller thieno)-azepin-pyrazin- og triazinderivater som mGluR-1-antagonister - Google Patents

Tetrahydro-(benzo eller thieno)-azepin-pyrazin- og triazinderivater som mGluR-1-antagonister

Info

Publication number
DK1345609T3
DK1345609T3 DK01271999T DK01271999T DK1345609T3 DK 1345609 T3 DK1345609 T3 DK 1345609T3 DK 01271999 T DK01271999 T DK 01271999T DK 01271999 T DK01271999 T DK 01271999T DK 1345609 T3 DK1345609 T3 DK 1345609T3
Authority
DK
Denmark
Prior art keywords
mglur
azepine
thieno
pyrazine
benzo
Prior art date
Application number
DK01271999T
Other languages
Danish (da)
English (en)
Inventor
Alfred Binggeli
Hans-Peter Maerki
Vincent Mutel
Maurice Wilhelm
Wolfgang Wostl
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK1345609T3 publication Critical patent/DK1345609T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DK01271999T 2000-12-22 2001-12-11 Tetrahydro-(benzo eller thieno)-azepin-pyrazin- og triazinderivater som mGluR-1-antagonister DK1345609T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00128329 2000-12-22
PCT/EP2001/014527 WO2002051418A1 (en) 2000-12-22 2001-12-11 Tetrahydro-(benzo or thieno)-azepine-pyrazine and triazine derivatives as mglur 1 antagonists
EP01271999A EP1345609B1 (en) 2000-12-22 2001-12-11 Tetrahydro-(benzo or thieno)-azepine-pyrazine and triazine derivatives as mglur 1 antagonists

Publications (1)

Publication Number Publication Date
DK1345609T3 true DK1345609T3 (da) 2005-10-03

Family

ID=8170787

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01271999T DK1345609T3 (da) 2000-12-22 2001-12-11 Tetrahydro-(benzo eller thieno)-azepin-pyrazin- og triazinderivater som mGluR-1-antagonister

Country Status (17)

Country Link
US (1) US6586422B2 (enExample)
EP (1) EP1345609B1 (enExample)
JP (1) JP4077319B2 (enExample)
KR (1) KR100545906B1 (enExample)
CN (1) CN1260226C (enExample)
AR (1) AR032379A1 (enExample)
AT (1) ATE297734T1 (enExample)
AU (1) AU2002216095B2 (enExample)
BR (1) BR0116378A (enExample)
CA (1) CA2432077C (enExample)
DE (1) DE60111568T2 (enExample)
DK (1) DK1345609T3 (enExample)
ES (1) ES2243400T3 (enExample)
MX (1) MXPA03005515A (enExample)
PT (1) PT1345609E (enExample)
WO (1) WO2002051418A1 (enExample)
ZA (1) ZA200304557B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2275096A3 (en) 2005-08-26 2011-07-13 Braincells, Inc. Neurogenesis via modulation of the muscarinic receptors
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
EP1981337B1 (en) * 2006-01-19 2015-09-02 Athersys, Inc. Thiophenyl azepines as serotonin 5-ht2c receptor ligands and uses thereof
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
WO2008030651A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
KR101100864B1 (ko) * 2009-06-12 2012-01-02 양준호 자동차 광택기용 광택패드

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3136654A1 (de) 1981-09-16 1983-03-31 Zahnradfabrik Friedrichshafen Ag, 7990 Friedrichshafen Linearverschieblicher arbeitsarm, insbesondere fuer handhabungsgeraete
WO1999044639A1 (en) * 1998-03-03 1999-09-10 Yamanouchi Pharmaceutical Co., Ltd. Remedies for brain infarction
ID29095A (id) * 1998-10-02 2001-07-26 Novartis Ag Cs Antagonis mglur5 untuk pengobatan rasa sakit dan kegelisahan
GB9823847D0 (en) * 1998-11-02 1998-12-23 Lilly Co Eli Pharmaceutical compounds
ES2209728T3 (es) * 1999-08-06 2004-07-01 F. Hoffmann-La Roche Ag Tetrahidro-benzo(d)azepinas y su uso como antagonistas de receptores de glutamato metabotropico.
EP1074549B1 (en) * 1999-08-06 2003-11-19 F. Hoffmann-La Roche Ag Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors

Also Published As

Publication number Publication date
PT1345609E (pt) 2005-08-31
ZA200304557B (en) 2004-09-13
ES2243400T3 (es) 2005-12-01
CN1487831A (zh) 2004-04-07
EP1345609B1 (en) 2005-06-15
US6586422B2 (en) 2003-07-01
CA2432077C (en) 2011-01-18
CN1260226C (zh) 2006-06-21
MXPA03005515A (es) 2003-09-25
JP4077319B2 (ja) 2008-04-16
AR032379A1 (es) 2003-11-05
US20020123488A1 (en) 2002-09-05
KR100545906B1 (ko) 2006-01-26
CA2432077A1 (en) 2002-07-04
ATE297734T1 (de) 2005-07-15
KR20030062444A (ko) 2003-07-25
WO2002051418A1 (en) 2002-07-04
BR0116378A (pt) 2003-10-28
DE60111568T2 (de) 2006-05-11
DE60111568D1 (de) 2005-07-21
EP1345609A1 (en) 2003-09-24
JP2004517850A (ja) 2004-06-17
AU2002216095B2 (en) 2005-12-01

Similar Documents

Publication Publication Date Title
NO20026125L (no) Tetrahydropyridin- eller piperidin-heterocykliske derivater
NO20035485L (no) Tiofenderivater som antivirale midler for flavivirusinfeksjon
DE60120076D1 (de) Schwach gefärbtes glass mit hoher durchlässigkeit
NO20015365L (no) Piperidinderivater som er anvendbare som CCR5-antagonister
NO20021459D0 (no) Piperazin-derivater som 5-HT1B-antagonister
NO20013945L (no) Fremstilling av isoflavonderivater
NO20022573D0 (no) N6-heterosykliske, 8-modifiserte adenosinderivater
NO20015366L (no) Piperazinderivater som er anvendbare som CCR5-antagonister
NO20010521D0 (no) Boreturbin
ITMI20000328A0 (it) Derivati della 4-fenil-piridina
HUP0202578A3 (en) Novel derivatives of flavones, xanthones and coumarins
PT1360184E (pt) Derivados de piperidina como antagonistas da neuroquinina 1
NO20023293D0 (no) Piperidin- og piperazinderivater som virker som 5-HT2A- reseptorantagonister
ATE334114T1 (de) Substituierte c-cyclohexylmethylamin-derivate
MXPA03005515A (es) Derivados de tetrahidro-(benzo o tieno)-azepina-pirazina y triazina como antagonistas de mglur 1.
PT1216250E (pt) Derivados propilicos substituidos de tienoisoxazolil- e tienilpirrazolil-fenoxi uteis como antagonistas d4
ATE370944T1 (de) Chromenon- und chromanonderivate als integrinhemmer
NO20022985D0 (no) Substituerte aminometyl-fenyl-cykloheksanderivater
ATE403646T1 (de) Aminocyclohexan-derivate
AR028607A1 (es) Derivados de 1,4-diazepan-2,5-diona
PT1322592E (pt) Derivados substituidos de 1-aminobutan-3-ol
ATE281436T1 (de) Chinolin-4-yl-derivate
DE60214408D1 (de) 5-METHOXY-8-ARYL-i1,2,4öTRIAZOLOi1,5-AöPYRIDINE DERIVATIVE ALS ADENOSIN-REZEPTOR ANTAGONISTEN
NO20042980L (no) 3,4-dihydro-1H-isokinolin-2-yl-derivater
DK1088818T3 (da) Quinolin-4-yl-derivater